APN_Jim McCambridge.pdf
•
0 likes•20 views
This document summarizes Jim McCambridge's presentation on evidence regarding the alcohol industry's scientific and political strategies. It discusses: 1) The World Health Assembly (WHA) approved the Global Alcohol Action Plan (GAAP) in 2022, which aims to make alcohol a lower public health priority and limit industry interference in health policies. 2) GAAP provides a changed view of the alcohol industry as primarily a threat to health. Achieving GAAP's goals requires resources and public health engagement. 3) The WHA's 2023 "best buys" for alcohol policies include increasing alcohol taxes, restricting alcohol advertising, and limiting hours of alcohol sales. GAAP aims for 70% of countries adopting these
Report
Share
Report
Share
Download to read offline
Recommended
Trends in the development of the domestic spa market by BISHTA, IHTA & APSP
Conference dealing with Trends in the development of the domestic spa market by Chris Hayes (BISHTA), Larry Caniglia (APSP), Bob Lauter (IHTA) and Christopher Robinson (IHTA), held during Piscine Global Europe 2018.
3rd National Alcohol Forum Conference
This document summarizes a presentation on alcohol marketing and youth. It discusses the global burden of alcohol on youth and evidence that exposure to alcohol marketing is associated with increased likelihood of drinking initiation and increased consumption among youth. It outlines various forms of alcohol marketing, including advertising in media favored by youth. Studies show youth are more receptive to ads incorporating music, people and stories. Alcohol companies have increasingly used social media like Facebook, though research on effects has not kept pace. The presentation argues for community responses and policies to reduce youth exposure to alcohol marketing.
Future Value Chain_2022
The document identifies two megatrends - Digital World and Fight for Resources - that will significantly impact the consumer goods and retail industry in the coming years. It then outlines three initiatives for collaborative industry action to address these megatrends: a Consumer Engagement Protocol to establish guidelines for digital engagement with consumers, a Next-Generation Product Identification initiative to transform product identification and information, and a Sustainable Packaging Consortium to improve packaging sustainability across the value chain.
Merck- Reviewing Corporate Sustainability_DOBA_DC_pptx.pdf
The document provides an analysis of the chemical and biopharmaceutical industries with a focus on sustainability priorities of GSK and Merck Inc. It discusses key challenges around environmental, social and economic sustainability. Both companies have set goals around reducing emissions, sourcing renewable energy and engaging suppliers. The recommendations include partnerships across multiple stakeholders to support resilient and sustainable healthcare. Areas for further focus include supporting additional UN SDGs like No Hunger and Sustainable Cities/Communities.
COVID-19 Product Development and Clinical Trials: Considerations from Europea...
Join experts from Medpace’s regulatory and operational teams in this webinar as they provide insights and considerations on how to accelerate product development for COVID-19 during different stages
Liquid Biopsy - TOC, Industry Report By Products and Services, Therapeutic Ap...
This document provides an overview and analysis of the Latin America liquid biopsy market from 2019-2025. It discusses key market drivers such as the potential of liquid biopsy and growing prominence of precision medicine. The market is segmented by product type, circulating biomarkers, clinical applications, therapeutic applications, and country. Major companies discussed include Biocept, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Guardant Health, Illumina, and Qiagen N.V. The Latin America liquid biopsy market is expected to grow from $XX million in 2017 to $XX million in 2025 with increasing adoption for treatment monitoring, prognosis, and screening applications. Brazil, Mexico, and Argentina are identified as the largest country markets.
Lessons from MESAS: Monitoring and Evaluating Scotland's Alcohol Strategy (ME...
Lessons from MESAS: Monitoring and Evaluating Scotland's Alcohol Strategy (ME...Institute of Public Health in Ireland
The MESAS approach to evaluating Scotland's alcohol strategy and minimum unit pricing policy focuses on building a robust evidence base through a portfolio of quantitative and qualitative studies. It aims to determine the policy's impact on alcohol consumption and harms while considering external factors, and to communicate findings in a way that informs the upcoming parliamentary vote without becoming too politicized. The evaluation emphasizes theoretical frameworks, mixed methods, transparency, stakeholder engagement, and maintaining its credibility and independence to ensure its findings can guide the future of the policy.Alcohol - From Action to Awareness, Dr. Peter Rice - SHAAP
This document summarizes Scotland's experience addressing alcohol-related harms and the key factors in their progress. It discusses:
- Rising alcohol deaths in Scotland from 1980-2003 and the strategic aims of the alcohol industry to influence policymaking.
- Scotland's minimum unit pricing legislation being challenged but ultimately upheld in court as an appropriate health measure.
- Early signs that alcohol deaths in Scotland have started falling after 20 years of increases, potentially helped by the recession.
- Lessons learned including using data, having an overall strategy while focusing on priorities, involving different organizations based on their strengths, and understanding industry obligations while needing both luck and skill as progress does not end.
Recommended
Trends in the development of the domestic spa market by BISHTA, IHTA & APSP
Conference dealing with Trends in the development of the domestic spa market by Chris Hayes (BISHTA), Larry Caniglia (APSP), Bob Lauter (IHTA) and Christopher Robinson (IHTA), held during Piscine Global Europe 2018.
3rd National Alcohol Forum Conference
This document summarizes a presentation on alcohol marketing and youth. It discusses the global burden of alcohol on youth and evidence that exposure to alcohol marketing is associated with increased likelihood of drinking initiation and increased consumption among youth. It outlines various forms of alcohol marketing, including advertising in media favored by youth. Studies show youth are more receptive to ads incorporating music, people and stories. Alcohol companies have increasingly used social media like Facebook, though research on effects has not kept pace. The presentation argues for community responses and policies to reduce youth exposure to alcohol marketing.
Future Value Chain_2022
The document identifies two megatrends - Digital World and Fight for Resources - that will significantly impact the consumer goods and retail industry in the coming years. It then outlines three initiatives for collaborative industry action to address these megatrends: a Consumer Engagement Protocol to establish guidelines for digital engagement with consumers, a Next-Generation Product Identification initiative to transform product identification and information, and a Sustainable Packaging Consortium to improve packaging sustainability across the value chain.
Merck- Reviewing Corporate Sustainability_DOBA_DC_pptx.pdf
The document provides an analysis of the chemical and biopharmaceutical industries with a focus on sustainability priorities of GSK and Merck Inc. It discusses key challenges around environmental, social and economic sustainability. Both companies have set goals around reducing emissions, sourcing renewable energy and engaging suppliers. The recommendations include partnerships across multiple stakeholders to support resilient and sustainable healthcare. Areas for further focus include supporting additional UN SDGs like No Hunger and Sustainable Cities/Communities.
COVID-19 Product Development and Clinical Trials: Considerations from Europea...
Join experts from Medpace’s regulatory and operational teams in this webinar as they provide insights and considerations on how to accelerate product development for COVID-19 during different stages
Liquid Biopsy - TOC, Industry Report By Products and Services, Therapeutic Ap...
This document provides an overview and analysis of the Latin America liquid biopsy market from 2019-2025. It discusses key market drivers such as the potential of liquid biopsy and growing prominence of precision medicine. The market is segmented by product type, circulating biomarkers, clinical applications, therapeutic applications, and country. Major companies discussed include Biocept, Bio-Rad Laboratories, F. Hoffmann-La Roche AG, Guardant Health, Illumina, and Qiagen N.V. The Latin America liquid biopsy market is expected to grow from $XX million in 2017 to $XX million in 2025 with increasing adoption for treatment monitoring, prognosis, and screening applications. Brazil, Mexico, and Argentina are identified as the largest country markets.
Lessons from MESAS: Monitoring and Evaluating Scotland's Alcohol Strategy (ME...
Lessons from MESAS: Monitoring and Evaluating Scotland's Alcohol Strategy (ME...Institute of Public Health in Ireland
The MESAS approach to evaluating Scotland's alcohol strategy and minimum unit pricing policy focuses on building a robust evidence base through a portfolio of quantitative and qualitative studies. It aims to determine the policy's impact on alcohol consumption and harms while considering external factors, and to communicate findings in a way that informs the upcoming parliamentary vote without becoming too politicized. The evaluation emphasizes theoretical frameworks, mixed methods, transparency, stakeholder engagement, and maintaining its credibility and independence to ensure its findings can guide the future of the policy.Alcohol - From Action to Awareness, Dr. Peter Rice - SHAAP
This document summarizes Scotland's experience addressing alcohol-related harms and the key factors in their progress. It discusses:
- Rising alcohol deaths in Scotland from 1980-2003 and the strategic aims of the alcohol industry to influence policymaking.
- Scotland's minimum unit pricing legislation being challenged but ultimately upheld in court as an appropriate health measure.
- Early signs that alcohol deaths in Scotland have started falling after 20 years of increases, potentially helped by the recession.
- Lessons learned including using data, having an overall strategy while focusing on priorities, involving different organizations based on their strengths, and understanding industry obligations while needing both luck and skill as progress does not end.
8th biosimilars congregation 2016
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
8th biosimilars congregation 2016
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
Presentation may 2014 rmit sustainability and integrated reporting
This document discusses sustainability and integrated reporting. It begins by outlining the objectives of the presentation, which are to share knowledge on sustainability and integrated reporting, provide case studies and resources, discuss various aspects of sustainability reporting, and provide insight into changes to business models. It then covers topics like the different meanings of sustainability, key aspects of sustainability from an environmental perspective, and resources on sustainability reporting frameworks and standards. The document argues that integrated reporting is an evolution that links strategy, governance, and financial performance with social, environmental and economic context to help businesses make more sustainable decisions and provide better information to stakeholders.
Value chain of soft drink industry
This document provides an overview of the soft drink industry supply chain and its major players. It discusses how the industry is made up of syrup producers like Coca-Cola and PepsiCo that manufacture flavoring syrups and concentrates, and bottlers that blend the syrups with other ingredients and package the drinks. It also covers the distribution channels that get the drinks to consumers, as well as marketing and the major product segments. The largest segment is carbonated soft drinks, while the leading brands are Coca-Cola, Pepsi, and Gatorade. Supermarkets are the major sales channel for these drinks.
Good Clinical Practice Guideline – a standard for clinical trials
The Good Clinical Practice (GCP) Guideline stands as a universally recognized standard for the conduct of clinical trials in the field of medical research. GCP sets forth a comprehensive framework of ethical and quality principles to ensure the safety, rights, and well-being of human research participants and the reliability of trial data. Encompassing all stages of clinical research, from study design to reporting of results, GCP serves as a guiding compass, promoting the highest standards of trial conduct, data integrity, and regulatory compliance. By adhering to GCP, researchers, sponsors, and regulatory authorities collaborate to uphold the trust and integrity of clinical trials, thereby fostering the development of safe and efficacious medical interventions for the benefit of patients and public health.
Chris Littlecott CCS Dialogue Presentation 090908
This document summarizes an introductory presentation given at a stakeholder dialogue on accelerating commercialization of carbon capture and storage (CCS) in the UK. The presentation outlines why the UK may be well positioned to deliver CCS, discusses different stakeholder interests in terms of investor and climate confidence, and poses questions to guide discussion. Key points include the UK's technical and political advantages for CCS, a framework for understanding stakeholder positions, and identifying criteria for a successful CCS policy. The goal of the dialogue is to improve understanding and enable stakeholders to identify policy measures that can accelerate CCS investment and emissions reductions.
Sustainable Consumption and Production and Carbon Labeling
A presentation on how carbon labels contribute on SCP and the challenges associated with their adoptions.
Next Generation Nicotine Delivery USA 2018
Next Generation Nicotine Delivery USA brings together strategic leaders from across the new nicotine products category i.e. E-Cigarettes, E-Liquids, Pharmaceuticals, together with solution providers for 2 days of insight, discussion and debate into how US manufacturers can –
Understand and adhere to US FDA’s PMTA regulations
Explore international sales opportunities and adhere to local regulation within these regions
Introduce consumer trends from local and international markets to increase sales at home and abroad
This is a strategic event targeted at those who have commercial or regulatory responsibility.
SMi Group's 4th annual Biosimilars & Biobetters conference
This document provides information about the "Biosimilars & Biobetters" conference being held on October 1-2, 2013 in London. The conference will discuss guidelines for biosimilars and biobetters from regulatory bodies, market access pathways, intellectual property, clinical development processes, and case studies on successful products. It will also feature two half-day workshops on developing marketing plans and the commercial realities of biosimilars. The conference is aimed at professionals in areas like regulatory affairs, clinical development, marketing, and intellectual property for pharmaceutical and biotechnology companies.
2013 Impact Summit: Transparency & Equity
Commissioner Choucair's presentation at the 2013 Community Indicators Consortium's Impact Summit: Transparency & Equity in Chicago.
Innovation Needs 2015
The document outlines industry needs for innovation in science and technology to support the food and drink supply chain from 2015-2017. It was produced by Campden BRI after an extensive consultation with over 3,000 industrial stakeholders across the supply chain. The document identifies needs in areas like safety, quality, nutrition, sustainability and skills across primary production, manufacturing, product development and the consumer end of the supply chain. It aims to encourage targeted research and development to address the needs raised by industry.
P 151 biosimilars & biobetters
This document provides information about a conference on biosimilars taking place from September 30th to October 1st, 2015 in London. The conference will discuss the evolving regulatory landscape for biosimilar approval in the US and Europe, market access challenges, protein characterization, and analytical comparability. It includes an agenda with sessions on the regulatory processes, patent litigation, pharmacovigilance, clinical development strategies, and analytical techniques for assessing biosimilarity. Pre-conference and post-conference workshops will provide more in-depth discussions of these topics.
A Public Health Perspective
The seminar discussed using arts and culture to address public health challenges like non-communicable diseases. It outlined the evidence that activities like singing, art therapy, and public art experiences can benefit mental health, dementia, physical activity and well-being. It encouraged cultural organizations to work with public health commissioners and demonstrate how their interventions meet health outcomes. Looking ahead, it said arts and culture can help address issues like social isolation among aging populations, but activities need to clearly align with local priorities and raise awareness of the evidence of their health benefits.
presentation on voluntary carbon market.pptx
The voluntary carbon market is experiencing explosive growth but lacks standards for high-quality carbon credits. WWF-US and EDF are working on a solution called the Carbon Credit Guidance for Buyers (CCG4B) project to provide clear, authoritative ratings and guidance for carbon credit buyers. Phase 1 defined criteria for assessing carbon credit quality through stakeholder consultation. Future phases will develop a robust methodology, apply ratings to project types, and publish a report endorsing guidance on responsible purchasing, navigating the market, and making mitigation claims. The CCG4B aims to help buyers, project developers, and policymakers determine and improve carbon credit quality.
Ev 20140612 c09_en
The Global Alliance for Chronic Diseases (GACD) facilitates international collaboration on research into chronic diseases in low and middle income countries. It aims to generate evidence to inform health policies and supports implementation research through funding projects. The GACD has members from several countries and organizations, including the European Commission. It has provided over $23 million in funding across 15 projects studying hypertension in 15 countries. The GACD is currently funding over $40 million in research on type 2 diabetes through a joint call with its members.
Oxygenated Drinks - Analysis and Kick Off
Make this ppt that align with the market trends of the soft drinks industry.
EC APN 22 6 23.pdf
The document provides an update on the WHO/EU Evidence into Action Alcohol Project (EVID-ACTION). It discusses the project's focus on reducing alcohol consumption and related harms. Several upcoming activities and studies are mentioned, including workshops on brief interventions, health warnings, digital marketing, and communications. The project aims to strengthen capacity and support evidence-based alcohol policies among EU member states.
COVID-19 and the beef and dairy sector in Colombia: Current and potential dev...
Poster prepared by Stefan Burkart, CIAT, for the Virtual Livestock CRP Planning Meeting, 8-17 June 2020
Chapter 13Products and Services for ConsumersCopyright © 2
Chapter 13
Products and Services for Consumers
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
Learning Objectives
LO1 The importance of offering a product suitable for the intended market
LO2 The importance of quality and how quality is defined
LO3 Physical, mandatory, and cultural requirements for product adaptation
LO4 The need to view all attributes of a product to overcome resistance to acceptance
LO5 Country-of-origin effects on product image
2
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
2
International Marketers: Opportunities and Challenges
New consumers are springing up in many emerging markets globally; some of these emerging markets have little purchasing power today, but they promise to be huge markets in the future.
In the more mature markets, consumers’ tastes are more sophisticated and complex as increases in purchasing power provide them with the means of satisfying new demands.
The distinction between products and services for some companies means little.
The governmental agencies that keep track of international trade still maintain the questionable product–service distinction.
U.S. exports target consumers, with the totals evenly split among the three major categories.
3
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
3
Product Adaptation
Product adaptation is important for both small and larger global companies.
As competition for world markets intensifies, selling what is produced for the domestic market in the same manner as it is sold at home is less effective.
Some products cannot be sold at all in foreign markets without modification.
Others may be sold as is, but their acceptance is greatly enhanced when tailored specifically to market needs.
4
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
4
Quality
Global competition is placing new emphasis on some basic tenets of business.
Product life cycles are becoming shorter focusing on:
Importance of quality
Competitive prices and
Innovative products
The power is shifting from seller to the buyer.
The customer defines quality in terms of his or her needs and resources.
In most global markets, a product’s cost and quality are among the most important criteria for purchases.
5
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
5
Quality Defined
Quality can be defined on two dimensions:
market-perceived quality and
performance quality
Consumer perceptions of a quality product often have more to do with market-perceived q ...
Nutritional Bar Market Report: Industry Outlook, Latest Development and Trends
According to the latest report by IMARC Group, titled " Nutritional Bar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025," The global nutritional bar market grew at a CAGR of nearly 5% during 2014-2019.
To learn more about this market, visit us at: https://www.imarcgroup.com/nutritional-bar-market
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The report has categorized the market based on vehicle type, propulsion type, application, battery type, battery capacity and region.
For more information, request for a free sample report here: https://www.imarcgroup.com/nutritional-bar-market/requestsample
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
IOGT-NTO.pdf
The document analyzes strategies used by the alcohol industry to influence public policy on alcohol and health. It identifies four key strategies: (1) Denial of the causal link between alcohol and health harms; (2) Distortion of the scientific evidence on health risks; (3) Distraction by emphasizing other risk factors; and (4) Distinction by appealing to cultural traditions. It provides examples of these strategies used by industry groups in opposing public health warnings and policies in Ireland and at the EU level. The document concludes that the alcohol industry's influence poses a democratic problem by disregarding public health evidence in favor of corporate profits.
APN_Sheila Gilheany.pdf
This document summarizes the key points from a presentation on alcohol labeling regulations in Ireland. It discusses the high rates of alcohol-related harm in Ireland including alcohol use disorders and deaths. It outlines Ireland's Public Health Alcohol Act of 2018 which includes provisions for minimum unit pricing and health warnings on labels. The process by which Ireland notified and finalized regulations for health warnings on labels is described, including responses from the EU and World Trade Organization. Other international developments in alcohol labeling are also mentioned.
More Related Content
Similar to APN_Jim McCambridge.pdf
8th biosimilars congregation 2016
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
8th biosimilars congregation 2016
8th Biosimilars Congregation 2016 conference which is taking place at 08th & 09th March 2016, The Kensington Close Hotel, Wrights Lane, London, UK.
For more details and registration simply email your interest and queries to Email – Deepak@virtueinsight.co.in
Best Regards,
Deepak Raj
Delegate and Sponsorship Sales
Virtue Insight
Gsm - + 91 9171350244
Tel - + 91 44 65515693
Skype - edeepakraj143
Presentation may 2014 rmit sustainability and integrated reporting
This document discusses sustainability and integrated reporting. It begins by outlining the objectives of the presentation, which are to share knowledge on sustainability and integrated reporting, provide case studies and resources, discuss various aspects of sustainability reporting, and provide insight into changes to business models. It then covers topics like the different meanings of sustainability, key aspects of sustainability from an environmental perspective, and resources on sustainability reporting frameworks and standards. The document argues that integrated reporting is an evolution that links strategy, governance, and financial performance with social, environmental and economic context to help businesses make more sustainable decisions and provide better information to stakeholders.
Value chain of soft drink industry
This document provides an overview of the soft drink industry supply chain and its major players. It discusses how the industry is made up of syrup producers like Coca-Cola and PepsiCo that manufacture flavoring syrups and concentrates, and bottlers that blend the syrups with other ingredients and package the drinks. It also covers the distribution channels that get the drinks to consumers, as well as marketing and the major product segments. The largest segment is carbonated soft drinks, while the leading brands are Coca-Cola, Pepsi, and Gatorade. Supermarkets are the major sales channel for these drinks.
Good Clinical Practice Guideline – a standard for clinical trials
The Good Clinical Practice (GCP) Guideline stands as a universally recognized standard for the conduct of clinical trials in the field of medical research. GCP sets forth a comprehensive framework of ethical and quality principles to ensure the safety, rights, and well-being of human research participants and the reliability of trial data. Encompassing all stages of clinical research, from study design to reporting of results, GCP serves as a guiding compass, promoting the highest standards of trial conduct, data integrity, and regulatory compliance. By adhering to GCP, researchers, sponsors, and regulatory authorities collaborate to uphold the trust and integrity of clinical trials, thereby fostering the development of safe and efficacious medical interventions for the benefit of patients and public health.
Chris Littlecott CCS Dialogue Presentation 090908
This document summarizes an introductory presentation given at a stakeholder dialogue on accelerating commercialization of carbon capture and storage (CCS) in the UK. The presentation outlines why the UK may be well positioned to deliver CCS, discusses different stakeholder interests in terms of investor and climate confidence, and poses questions to guide discussion. Key points include the UK's technical and political advantages for CCS, a framework for understanding stakeholder positions, and identifying criteria for a successful CCS policy. The goal of the dialogue is to improve understanding and enable stakeholders to identify policy measures that can accelerate CCS investment and emissions reductions.
Sustainable Consumption and Production and Carbon Labeling
A presentation on how carbon labels contribute on SCP and the challenges associated with their adoptions.
Next Generation Nicotine Delivery USA 2018
Next Generation Nicotine Delivery USA brings together strategic leaders from across the new nicotine products category i.e. E-Cigarettes, E-Liquids, Pharmaceuticals, together with solution providers for 2 days of insight, discussion and debate into how US manufacturers can –
Understand and adhere to US FDA’s PMTA regulations
Explore international sales opportunities and adhere to local regulation within these regions
Introduce consumer trends from local and international markets to increase sales at home and abroad
This is a strategic event targeted at those who have commercial or regulatory responsibility.
SMi Group's 4th annual Biosimilars & Biobetters conference
This document provides information about the "Biosimilars & Biobetters" conference being held on October 1-2, 2013 in London. The conference will discuss guidelines for biosimilars and biobetters from regulatory bodies, market access pathways, intellectual property, clinical development processes, and case studies on successful products. It will also feature two half-day workshops on developing marketing plans and the commercial realities of biosimilars. The conference is aimed at professionals in areas like regulatory affairs, clinical development, marketing, and intellectual property for pharmaceutical and biotechnology companies.
2013 Impact Summit: Transparency & Equity
Commissioner Choucair's presentation at the 2013 Community Indicators Consortium's Impact Summit: Transparency & Equity in Chicago.
Innovation Needs 2015
The document outlines industry needs for innovation in science and technology to support the food and drink supply chain from 2015-2017. It was produced by Campden BRI after an extensive consultation with over 3,000 industrial stakeholders across the supply chain. The document identifies needs in areas like safety, quality, nutrition, sustainability and skills across primary production, manufacturing, product development and the consumer end of the supply chain. It aims to encourage targeted research and development to address the needs raised by industry.
P 151 biosimilars & biobetters
This document provides information about a conference on biosimilars taking place from September 30th to October 1st, 2015 in London. The conference will discuss the evolving regulatory landscape for biosimilar approval in the US and Europe, market access challenges, protein characterization, and analytical comparability. It includes an agenda with sessions on the regulatory processes, patent litigation, pharmacovigilance, clinical development strategies, and analytical techniques for assessing biosimilarity. Pre-conference and post-conference workshops will provide more in-depth discussions of these topics.
A Public Health Perspective
The seminar discussed using arts and culture to address public health challenges like non-communicable diseases. It outlined the evidence that activities like singing, art therapy, and public art experiences can benefit mental health, dementia, physical activity and well-being. It encouraged cultural organizations to work with public health commissioners and demonstrate how their interventions meet health outcomes. Looking ahead, it said arts and culture can help address issues like social isolation among aging populations, but activities need to clearly align with local priorities and raise awareness of the evidence of their health benefits.
presentation on voluntary carbon market.pptx
The voluntary carbon market is experiencing explosive growth but lacks standards for high-quality carbon credits. WWF-US and EDF are working on a solution called the Carbon Credit Guidance for Buyers (CCG4B) project to provide clear, authoritative ratings and guidance for carbon credit buyers. Phase 1 defined criteria for assessing carbon credit quality through stakeholder consultation. Future phases will develop a robust methodology, apply ratings to project types, and publish a report endorsing guidance on responsible purchasing, navigating the market, and making mitigation claims. The CCG4B aims to help buyers, project developers, and policymakers determine and improve carbon credit quality.
Ev 20140612 c09_en
The Global Alliance for Chronic Diseases (GACD) facilitates international collaboration on research into chronic diseases in low and middle income countries. It aims to generate evidence to inform health policies and supports implementation research through funding projects. The GACD has members from several countries and organizations, including the European Commission. It has provided over $23 million in funding across 15 projects studying hypertension in 15 countries. The GACD is currently funding over $40 million in research on type 2 diabetes through a joint call with its members.
Oxygenated Drinks - Analysis and Kick Off
Make this ppt that align with the market trends of the soft drinks industry.
EC APN 22 6 23.pdf
The document provides an update on the WHO/EU Evidence into Action Alcohol Project (EVID-ACTION). It discusses the project's focus on reducing alcohol consumption and related harms. Several upcoming activities and studies are mentioned, including workshops on brief interventions, health warnings, digital marketing, and communications. The project aims to strengthen capacity and support evidence-based alcohol policies among EU member states.
COVID-19 and the beef and dairy sector in Colombia: Current and potential dev...
Poster prepared by Stefan Burkart, CIAT, for the Virtual Livestock CRP Planning Meeting, 8-17 June 2020
Chapter 13Products and Services for ConsumersCopyright © 2
Chapter 13
Products and Services for Consumers
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
Learning Objectives
LO1 The importance of offering a product suitable for the intended market
LO2 The importance of quality and how quality is defined
LO3 Physical, mandatory, and cultural requirements for product adaptation
LO4 The need to view all attributes of a product to overcome resistance to acceptance
LO5 Country-of-origin effects on product image
2
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
2
International Marketers: Opportunities and Challenges
New consumers are springing up in many emerging markets globally; some of these emerging markets have little purchasing power today, but they promise to be huge markets in the future.
In the more mature markets, consumers’ tastes are more sophisticated and complex as increases in purchasing power provide them with the means of satisfying new demands.
The distinction between products and services for some companies means little.
The governmental agencies that keep track of international trade still maintain the questionable product–service distinction.
U.S. exports target consumers, with the totals evenly split among the three major categories.
3
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
3
Product Adaptation
Product adaptation is important for both small and larger global companies.
As competition for world markets intensifies, selling what is produced for the domestic market in the same manner as it is sold at home is less effective.
Some products cannot be sold at all in foreign markets without modification.
Others may be sold as is, but their acceptance is greatly enhanced when tailored specifically to market needs.
4
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
4
Quality
Global competition is placing new emphasis on some basic tenets of business.
Product life cycles are becoming shorter focusing on:
Importance of quality
Competitive prices and
Innovative products
The power is shifting from seller to the buyer.
The customer defines quality in terms of his or her needs and resources.
In most global markets, a product’s cost and quality are among the most important criteria for purchases.
5
Copyright © 2016 McGraw-Hill Education. All rights reserved. No reproduction or distribution without the prior written consent of McGraw-Hill Education.
5
Quality Defined
Quality can be defined on two dimensions:
market-perceived quality and
performance quality
Consumer perceptions of a quality product often have more to do with market-perceived q ...
Nutritional Bar Market Report: Industry Outlook, Latest Development and Trends
According to the latest report by IMARC Group, titled " Nutritional Bar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025," The global nutritional bar market grew at a CAGR of nearly 5% during 2014-2019.
To learn more about this market, visit us at: https://www.imarcgroup.com/nutritional-bar-market
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The report has categorized the market based on vehicle type, propulsion type, application, battery type, battery capacity and region.
For more information, request for a free sample report here: https://www.imarcgroup.com/nutritional-bar-market/requestsample
Contact Us:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800
Similar to APN_Jim McCambridge.pdf (20)
Presentation may 2014 rmit sustainability and integrated reporting
Presentation may 2014 rmit sustainability and integrated reporting
Good Clinical Practice Guideline – a standard for clinical trials
Good Clinical Practice Guideline – a standard for clinical trials
Sustainable Consumption and Production and Carbon Labeling
Sustainable Consumption and Production and Carbon Labeling
SMi Group's 4th annual Biosimilars & Biobetters conference
SMi Group's 4th annual Biosimilars & Biobetters conference
COVID-19 and the beef and dairy sector in Colombia: Current and potential dev...
COVID-19 and the beef and dairy sector in Colombia: Current and potential dev...
Chapter 13Products and Services for ConsumersCopyright © 2
Chapter 13Products and Services for ConsumersCopyright © 2
Nutritional Bar Market Report: Industry Outlook, Latest Development and Trends
Nutritional Bar Market Report: Industry Outlook, Latest Development and Trends
More from PonenciesASPCAT
IOGT-NTO.pdf
The document analyzes strategies used by the alcohol industry to influence public policy on alcohol and health. It identifies four key strategies: (1) Denial of the causal link between alcohol and health harms; (2) Distortion of the scientific evidence on health risks; (3) Distraction by emphasizing other risk factors; and (4) Distinction by appealing to cultural traditions. It provides examples of these strategies used by industry groups in opposing public health warnings and policies in Ireland and at the EU level. The document concludes that the alcohol industry's influence poses a democratic problem by disregarding public health evidence in favor of corporate profits.
APN_Sheila Gilheany.pdf
This document summarizes the key points from a presentation on alcohol labeling regulations in Ireland. It discusses the high rates of alcohol-related harm in Ireland including alcohol use disorders and deaths. It outlines Ireland's Public Health Alcohol Act of 2018 which includes provisions for minimum unit pricing and health warnings on labels. The process by which Ireland notified and finalized regulations for health warnings on labels is described, including responses from the EU and World Trade Organization. Other international developments in alcohol labeling are also mentioned.
APN EVIN LAW GALLOPEL.pdf
The document summarizes research analyzing the lobbying strategies used by the alcohol industry in France to undermine the Evin Law, which places restrictions on alcohol advertising. Through interviews with key stakeholders, the research found the industry engaged in strong lobbying that has weakened the law's enforcement since 1991. Some strategies included claiming regulations limited free speech, forming alliances with politicians, and focusing arguments on wine culture. The goal of the lobbying was to roll back limitations on advertising content and exposure to protect alcohol sales, especially to youth.
APN _CiaraGilmartin.pdf
The Language of Lobbying: A critical discourse analysis of Ireland's public health (alcohol) Bill Debate
Mesa_3.1_Panorama_Europeo_I.Indave.pdf
Panorama actual y retos para programas de dispensación de heroína en Europa. B. Iciar Indave, Marta Donat.
Mesa 3.3_ErinOMara_speech.pdf
This document provides an overview of a presentation on injectable drug treatment services. The presenter discusses their experience with both poor and exemplary services. They emphasize the importance of meaningful involvement of people who use drugs in developing services. Regulations and control that are overly punitive can undermine a service and cause people to drop out. The best services work collaboratively with clients and are flexible, trusting and aim to empower rather than control. Key tips include embracing user involvement, not capping doses, not making the clinic the center of life, and never using punishments. An ideal service is like one in their town that clients want to spend time at and feel safe.
Mesa 3.3_ErinMara_present_controlvsemmanc.pdf
This document discusses injectable prescribing in the UK. It shares insights and revelations from a drugs activist on their experience with injectable prescribing. Contact information is provided for the activist to discuss developing injectable services further.
Guia de Pràctica Clínica Alcohol menors joves i famílies.pdf
Guia de Pràctica Clínica Alcohol menors joves i famílies
3. Atenció primària.pdf
Eines i habilitats per a la detecció i intervenció del consum amb joves a la consulta.
Mesa_3.4. Experiencia_Vancouver_K.Lock.pdf
Tractament amb heroïna: una alternativa. Antecedents, situació actual i reptes de futur. Experiència Vancouver.
Mesa_3.2. Aspectos cl”nicos en el tratamiento asistido con hero”na. La experi...
El documento resume la experiencia del tratamiento asistido con heroína en Suiza desde sus orígenes en 1994 hasta la actualidad. Se divide en tres etapas: Los orígenes (1994-1999) como etapa experimental, La normalización (2000-2019) como etapa de consolidación, y El cambio de enfoque (2020-2030) como etapa de diversificación. Los ensayos clínicos iniciales mostraron que el tratamiento con heroína mejora la salud y la integración social de los pacientes. Actualmente hay 1600 pacientes en tratamiento en Suiza, con mejor
Mesa_3.1_Panorama_Europeo_I.Indave.pdf
Este documento presenta un resumen de los programas de tratamiento asistido con heroína en Europa y los retos para su implementación. Actualmente existen programas de tratamiento asistido con heroína en 5 países de la UE y 7 países europeos. Estos programas han demostrado reducir el uso de heroína y otras drogas ilegales, así como la delincuencia. Sin embargo, su implementación plantea retos como traducir la evidencia a la práctica clínica, obtener apoyo regulatorio y financiamiento, y superar los estigmas asociados con el trat
Mesa_2.3_Aspectos_legales_M.Rodriguez_AEMPS.pdf
Tractament amb heroïna: una alternativa. Antecedents, situació actual i reptes de futur. ASpectos legales y viabilidad en la implementación de programas de tratamiento con heroína en España.
Mesa_2.2_Diacetilm_oral_MiquelCasas.pdf
1. Se realizó un ensayo clínico en Cataluña para comparar la eficacia de la diacetilmorfina oral, la morfina oral y la metadona oral en el tratamiento de usuarios dependientes de heroína.
2. Los resultados mostraron que el 90% de los pacientes se mantuvieron en el estudio y que todos los tratamientos proporcionaron un alivio similar de los síntomas de abstinencia.
3. Los pacientes, enfermeras y médicos no pudieron distinguir cuál opioide estaban tomando los pacientes, lo
More from PonenciesASPCAT (20)
Guia de Pràctica Clínica Alcohol menors joves i famílies.pdf
Guia de Pràctica Clínica Alcohol menors joves i famílies.pdf
Mesa_3.2. Aspectos cl”nicos en el tratamiento asistido con hero”na. La experi...
Mesa_3.2. Aspectos cl”nicos en el tratamiento asistido con hero”na. La experi...
Recently uploaded
Breast cancer: Post menopausal endocrine therapy
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
une 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
This quiz was conducted as a promotional event for the 2024 Annual Meet of Kerala Chapter of API.
More than 20 participants took part everyday !
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Fallopian tube blockage may cause female infertility. For treatment, herbal medicine Fuyan Pill can be a solution.
Know the difference between Endodontics and Orthodontics.
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
SENSORY NEEDS B.SC. NURSING SEMESTER II.
Sensation is the neurological process by which we become aware of surrounding environment.
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...PVI, PeerView Institute for Medical Education
Co-Chairs, Val J. Lowe, MD, and Cyrus A. Raji, MD, PhD, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/AAPA activity titled “Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neuroradiology in Diagnosis and Treatment.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/3PvVY25. CME/AAPA credit will be available until June 28, 2025.The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Kosmoderma Academy Of Aesthetic Medicine
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Pollen and Fungal allergy: aeroallergy.pdf
Pollen and Fungal allergy: aeroallergy.pdfChulalongkorn Allergy and Clinical Immunology Research Group
Pollen and Fungal allergy
Presented by Chaloemchai Chumsaengchotsakul, MD.
June 14, 2024vonoprazan A novel drug for GERD presentation
Vonoprazan, a new potassium acid channel blocker used in the conditions of GERD and gastric ulcer, duodenal ulcer ....
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
low birth weight presentation. Low birth weight (LBW) infant is defined as the one whose birth weight is less than 2500g irrespective of their gestational age. Premature birth and low birth weight(LBW) is still a serious problem in newborn. Causing high morbidity and mortality rate worldwide. The nursing care provide to low birth weight babies is crucial in promoting their overall health and development. Through careful assessment, diagnosis,, planning, and evaluation plays a vital role in ensuring these vulnerable infants receive the specialize care they need. In India every third of the infant weight less than 2500g.
Birth period, socioeconomical status, nutritional and intrauterine environment are the factors influencing low birth weight
Cervical Disc Arthroplasty ORSI 2024.pptx
Indication and installation of a mobile cervical disc prosthesis. Benefits of the PRODISC C VIVO mobile disc prosthesis (Centinel Spine)
Recently uploaded (20)
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
June 2024 Oncology Cartoons By Dr Kanhu Charan Patro
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Demystifying Fallopian Tube Blockage- Grading the Differences and Implication...
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...
Alzheimer’s Disease Case Conference: Gearing Up for the Expanding Role of Neu...
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
APN_Jim McCambridge.pdf
- 1. An update on the evidence on the industry’s scientific and political strategies Jim McCambridge APN Symposium, Vilnius 22/06/23
- 2. GAAP approved 75th WHA 2022
- 3. • GAAP is more ambitious for health by 2030 and identifies that alcohol is a public health priority. • Policy interference by major alcohol companies is a key problem, as are commercial activities that are harmful to health. • GAAP provides a changed view of the alcohol industry, regarding it primarily now as a threat to health. • Achieving the ambitious aims of GAAP necessitates adequate resources and the active engagement of the public health community.
- 4. All changed, changed utterly: A terrible beauty is born WB Yeats, Easter 1916 Optimism, pessimism & realism… KBS presentation of analysis and prospects
- 5. 76th WHA 2023 alcohol best buys WHA 2023 Best buys • Increase excise taxes on alcoholic beverages • Enact and enforce bans or comprehensive restrictions on exposure to alcohol advertising (across multiple types of media) • Enact and enforce restrictions on the physical availability of retailed alcohol (via reduced hours of sale) (GAAP target 70% of countries implementing by 2030)
- 6. Transformative Research on the Alcohol Industry, Policy & Science Intro to TRAPS symposium, EAPC Oslo 17/06/22, by Prof. Jim McCambridge
- 7. APN one year ago • At that time…. • Approximately 50 papers in peer reviewed scientific journals, all are available free to access • Go to https://pubmed.ncbi.nlm.nih.gov/ & search ‘McCambridge AND industry’
- 15. Further papers on… • ICAP & IARD… • Historical policy/science papers • CVD research & industry funding • Funding decision-making by researchers • Merchant of doubt and boundary work by research community • Brief interventions 2.0 & industry • Alcohol policy advocacy during COVID • GAAP
- 17. Megatrend 1
- 18. Megatrend 1
- 19. Megatrend 1
- 20. Megatrend 1
- 21. Megatrend 2
- 22. Megatrend 2
- 23. Megatrend 2
- 27. GAAP operational principle “The development of public policies to reduce the harmful use of alcohol should be protected, in accordance with national laws, from commercial and other vested interests that can interfere with and undermine public health objectives”
- 28. Megatrend 2: CDoH frame • Alcohol industry conduct in comparative context • Conceptual work for empirical study • Wider audience • Politically diluted or astute? • High level endorsement • Opportunities & threat if alcohol focus lost or seen as siloed or too limited
- 29. Closing thoughts A year in the life of a field…it’s been quite a year Contexts will drive future megatrends in accumulation of evidence… Prospects for pinning down the alcohol industry uncertain, though evidence will advance Evidence accumulation can also underpin progress on alcohol policy and public health…